Linaclotide, a small protein targeting the GUCY2C receptor, is being evaluated for its efficacy in patients with stages 0-3 colorectal cancer and sporadic colorectal adenomas. The trial is sponsored by the Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University and is currently active but not recruiting. The market for colorectal cancer therapies is significant, with increasing demand for innovative treatments that can improve patient outcomes. If successful, linaclotide could enhance the therapeutic landscape for colorectal cancer, particularly in early-stage disease, potentially positioning it favorably against existing therapies. The collaboration with the U.S. Department of Defense may also provide additional funding and support for further development. Diligence should focus on the competitive landscape, particularly other agents targeting GUCY2C and their clinical progress.